HIV/AIDS

The latest HIV/AIDS news from UNC Health Care and the UNC School of Medicine.

Long-acting injectable implant shows promise for HIV treatment and prevention

Long-acting injectable implant shows promise for HIV treatment and prevention

The long-acting antiretroviral drug formulation, developed by UNC School of Medicine researchers Rahima Benhabbour, PhD and Martina Kovarova, PhD, is injected under the skin and forms into a solid implant that dissolves slowly to release anti-HIV medication over time.

Long-acting injectable implant shows promise for HIV treatment and prevention - Read More…

Proof-of-Concept HIV Immunotherapy Study Passes Phase 1 Safety Trial

Proof-of-Concept HIV Immunotherapy Study Passes Phase 1 Safety Trial

Julia Sung, MD, assistant professor of medicine in the Division of Infectious Diseases, has proven the safety of a new immunotherapy to re-educate the body’s immune system to better fight HIV infection. The results were recently published in the journal Molecular Therapy.

Proof-of-Concept HIV Immunotherapy Study Passes Phase 1 Safety Trial - Read More…

UNC Cure Center and Cell Microsystems Receive NIH Contract for Single Cell HIV Diagnostic Assay

UNC Cure Center and Cell Microsystems Receive NIH Contract for Single Cell HIV Diagnostic Assay

The University of North Carolina at Chapel Hill HIV Cure Center and Cell Microsystems, a provider of innovative tools and scalable solutions for the sorting and isolation of single cells, announced they have received an approximately $283,000, 12-month Phase I Small Business Innovation and Research (SBIR) contract from the National Institutes of Health (NIH) to develop an automated platform to quantify the latent HIV reservoir.

UNC Cure Center and Cell Microsystems Receive NIH Contract for Single Cell HIV Diagnostic Assay - Read More…

T cells alone are sufficient to establish and maintain HIV infection in the brain

T cells alone are sufficient to establish and maintain HIV infection in the brain

Led by J. Victor Garcia, PhD, UNC researchers report in the Journal of Clinical Investigation that T cells in the brain may be an important HIV reservoir that should be targeted by HIV cure approaches.

T cells alone are sufficient to establish and maintain HIV infection in the brain - Read More…

UNC to Test Therapeutic Vaccine in People Living with HIV

A multidisciplinary research team at the University of North Carolina at Chapel Hill has been awarded more than $5.6 million from the National Institutes of Health (NIH) to test a therapeutic vaccine in people living with HIV.

UNC to Test Therapeutic Vaccine in People Living with HIV - Read More…

UNC Study Advances the Ability to Expose Latent HIV

UNC Study Advances the Ability to Expose Latent HIV

UNC researchers led by Nancie Archin, PhD, and David Margolis, MD, have shown that interval dosing of the drug Vorinostat reverses HIV latency and is well-tolerated in people living with HIV. However, while Vorinostat makes latent HIV easier to detect, it does not clear or deplete infection, meaning additional advances will be needed to achieve a cure. These results were published in the Journal of Clinical Investigation on July 17.

UNC Study Advances the Ability to Expose Latent HIV - Read More…

UNC receives $18 million to develop mobile technology to prevent and treat HIV in adolescents

UNC receives $18 million to develop mobile technology to prevent and treat HIV in adolescents

iTech project will target people under the age of 30, the population with most new HIV infections in US. The effort is led by Lisa Hightow-Weidman, MD, MPH, associate professor of medicine.

UNC receives $18 million to develop mobile technology to prevent and treat HIV in adolescents - Read More…

Researchers Discuss Challenges, Successes of HIV Cure Research in Science

Researchers Discuss Challenges, Successes of HIV Cure Research in Science

A better understanding of HIV latency is the key to eradicating the virus researchers at the University of North Carolina and partner institutions write in a perspective in the journal Science.

Researchers Discuss Challenges, Successes of HIV Cure Research in Science - Read More…

HIV Treatment Keeps Uninfected Partner from Contracting the Virus

HIV Treatment Keeps Uninfected Partner from Contracting the Virus

Anti-HIV medications suppress the viral load of people living with HIV and provide durable protection against heterosexual transmission according to the groundbreaking study led by Myron Cohen, MD.

HIV Treatment Keeps Uninfected Partner from Contracting the Virus - Read More…

Infectious Disease Clinic Celebrates Early Heroes

Infectious Disease Clinic Celebrates Early Heroes

A recent gathering in the UNC Infectious Disease Clinic served as a reunion for the nurses and other medical staff who worked tirelessly to care for patients in the early days of the HIV/AIDS epidemic and ultimately led to the establishment of a dedicated clinic within the hospital for those patients.

Infectious Disease Clinic Celebrates Early Heroes - Read More…

 Early Antiretroviral Therapy Protects Sero-Discordant Couples from Transmission of HIV to Their Uninfected Partner

Early Antiretroviral Therapy Protects Sero-Discordant Couples from Transmission of HIV to Their Uninfected Partner

These findings demonstrate that antiretroviral therapy, when taken until viral suppression is achieved and sustained, is a highly effective, durable intervention for HIV prevention.

Early Antiretroviral Therapy Protects Sero-Discordant Couples from Transmission of HIV to Their Uninfected Partner - Read More…

Carolina, GSK announce novel partnership to accelerate search for HIV cure

Carolina, GSK announce novel partnership to accelerate search for HIV cure

The HIV Cure center will be located on the UNC-Chapel Hill campus and will focus exclusively on finding a cure for HIV/AIDS.

Carolina, GSK announce novel partnership to accelerate search for HIV cure - Read More…

Researchers identify timeline for HIV replication in the brain

Researchers identify timeline for HIV replication in the brain

A new study in PLoS Pathogens shows that HIV can infect the brain early on and should be combated as soon as possible with antiretroviral therapy to limit risk of dementia

Researchers identify timeline for HIV replication in the brain - Read More…

Becoming Less Super as a Specialist

Becoming Less Super as a Specialist

Dr. David Wohl, an HIV/AIDS specialist at UNC, reflects on the reasons why he now finds himself drawn to fighting Ebola.

Becoming Less Super as a Specialist - Read More…

Margolis collaboration featured in The New Yorker

Margolis collaboration featured in The New Yorker

UNC School of Medicine researcher David Margolis, MD, was one of the first researchers to resist the common view that HIV is an incurable infection

Margolis collaboration featured in The New Yorker - Read More…

UNC to partner in new global HIV/AIDS project

Supporting Operational AIDS Research (SOAR) is a global research project to determine how best to address challenges and gaps that remain in the delivery of HIV and AIDS care and support, treatment, and prevention services.

UNC to partner in new global HIV/AIDS project - Read More…

UNC receives $1.5 million grant to strengthen HIV/AIDS research training in South Africa

UNC receives $1.5 million grant to strengthen HIV/AIDS research training in South Africa

The University of North Carolina at Chapel Hill has received a $1.5 million grant aimed at strengthening HIV/AIDS research training in collaboration with the Wits School of Public Health at the University of the Witwatersrand in Johannesburg, South Africa.

UNC receives $1.5 million grant to strengthen HIV/AIDS research training in South Africa - Read More…

Several UNC faculty published in JAMA theme issue on HIV/AIDS

Several members of the UNC School of Medicine faculty had articles published in the Journal of the American Medical Association's (JAMA) July 23/30, 2014, HIV/AIDS theme issue.

Several UNC faculty published in JAMA theme issue on HIV/AIDS - Read More…

Share This: